LIMN — Liminatus Pharma Balance Sheet
0.000.00%
Last trade - 00:00- $22.97m
- $23.69m
Annual balance sheet for Liminatus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0 | 5.05 | 0.434 | 0.056 |
| Net Total Receivables | 0.054 | 0.1 | 0.945 | 3.67 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 2.69 | 6.84 | 2.24 | 5.28 |
| Net Property, Plant And Equipment | 0.001 | 0.001 | 0.001 | 0.001 |
| Long Term Notes Receivable | ||||
| Total Assets | 2.69 | 6.84 | 2.24 | 5.41 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 14.1 | 17.7 | 18 | 24.7 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 14.1 | 17.7 | 18 | 24.7 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | -11.4 | -10.8 | -15.8 | -19.3 |
| Total Liabilities & Shareholders' Equity | 2.69 | 6.84 | 2.24 | 5.41 |
| Total Common Shares Outstanding |